J M Pawlotsky

Summary

Country: France

Publications

  1. ncbi request reprint [Management of patients with hepatitis C virus infection. Virological tests]
    Jean Michel Pawlotsky
    Laboratoire de Virologie EA 3489, Hopital Henri Mondor, Universite Paris XII, Creteil
    Gastroenterol Clin Biol 26:B180-7. 2002
  2. ncbi request reprint Molecular diagnosis of viral hepatitis
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Gastroenterology 122:1554-68. 2002
  3. ncbi request reprint Antiviral action of ribavirin in chronic hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Gastroenterology 126:703-14. 2004
  4. ncbi request reprint Virology of hepatitis B and C viruses and antiviral targets
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris 12, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    J Hepatol 44:S10-3. 2006
  5. ncbi request reprint [New therapeutic strategies in chronic hepatitis C]
    Jean Michel Pawlotsky
    Gastroenterol Clin Biol 30:1009-11. 2006
  6. ncbi request reprint New hepatitis C therapies: the toolbox, strategies, and challenges
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France INSERM U955, Creteil, France Electronic address
    Gastroenterology 146:1176-92. 2014
  7. pmc Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    PLoS ONE 4:e8209. 2009
  8. ncbi request reprint What are the pros and cons of the use of host-targeted agents against hepatitis C?
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France INSERM U955, Creteil, France Electronic address
    Antiviral Res 105:22-5. 2014
  9. ncbi request reprint Hepatitis C virus: standard-of-care treatment
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Adv Pharmacol 67:169-215. 2013
  10. doi request reprint NS5A inhibitors in the treatment of hepatitis C
    Jean Michel Pawlotsky
    National Reference Centre for Viral Hepatitis B, C and delta, Department of Virology, Henri Mondor Hospital, University of Paris Est, Creteil, France INSERM U955, Creteil, France
    J Hepatol 59:375-82. 2013

Collaborators

Detail Information

Publications111 found, 100 shown here

  1. ncbi request reprint [Management of patients with hepatitis C virus infection. Virological tests]
    Jean Michel Pawlotsky
    Laboratoire de Virologie EA 3489, Hopital Henri Mondor, Universite Paris XII, Creteil
    Gastroenterol Clin Biol 26:B180-7. 2002
  2. ncbi request reprint Molecular diagnosis of viral hepatitis
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Gastroenterology 122:1554-68. 2002
    ..This article reviews current molecular biology-based techniques and assays, and their practical use in the management of hepatitis B and C virus infection...
  3. ncbi request reprint Antiviral action of ribavirin in chronic hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Gastroenterology 126:703-14. 2004
    ..Our aim was to assess the antiviral action of ribavirin on hepatitis C virus (HCV) as a function of ribavirin pharmacokinetics and to evaluate the influence of this antiviral effect on IFN-alpha efficacy...
  4. ncbi request reprint Virology of hepatitis B and C viruses and antiviral targets
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris 12, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    J Hepatol 44:S10-3. 2006
    ..The issue of cccDNA clearance, however, remains in hepatitis B treatment, whereas HCV infection is curable...
  5. ncbi request reprint [New therapeutic strategies in chronic hepatitis C]
    Jean Michel Pawlotsky
    Gastroenterol Clin Biol 30:1009-11. 2006
  6. ncbi request reprint New hepatitis C therapies: the toolbox, strategies, and challenges
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France INSERM U955, Creteil, France Electronic address
    Gastroenterology 146:1176-92. 2014
    ..Strategic choices, cost issues, HCV screening, and improving access to care in resource-constrained areas also are discussed. ..
  7. pmc Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    PLoS ONE 4:e8209. 2009
    ..The goal of this study was to identify the appropriate molecular tool(s) for accurate HCV genotype 1 subtype determination...
  8. ncbi request reprint What are the pros and cons of the use of host-targeted agents against hepatitis C?
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France INSERM U955, Creteil, France Electronic address
    Antiviral Res 105:22-5. 2014
    ..This article forms part of a symposium in Antiviral Research on "Hepatitis C: next steps toward global eradication." ..
  9. ncbi request reprint Hepatitis C virus: standard-of-care treatment
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Adv Pharmacol 67:169-215. 2013
    ....
  10. doi request reprint NS5A inhibitors in the treatment of hepatitis C
    Jean Michel Pawlotsky
    National Reference Centre for Viral Hepatitis B, C and delta, Department of Virology, Henri Mondor Hospital, University of Paris Est, Creteil, France INSERM U955, Creteil, France
    J Hepatol 59:375-82. 2013
    ..Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens. ..
  11. doi request reprint Treatment of chronic hepatitis C: current and future
    Jean Michel Pawlotsky
    Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Curr Top Microbiol Immunol 369:321-42. 2013
    ..This chapter provides an overview of the current treatment of HCV infection and discusses the future of HCV therapy with new anti-HCV drugs...
  12. doi request reprint Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Jean Michel Pawlotsky
    Department of Virology, Hopital Henri Mondor, Universite Paris Est, 51 Avenue du Marechal de Lattre de Tassigny, 94010, Creteil, France
    Curr Gastroenterol Rep 15:309. 2013
    ..Whether response-guided therapy will still be useful in the era of all-oral, interferon-free regimens remains uncertain...
  13. doi request reprint The science of direct-acting antiviral and host-targeted agent therapy
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Antivir Ther 17:1109-17. 2012
    ..Further results are awaited that will allow the establishment of an ideal first-line all-oral, interferon-free treatment regimen for patients with chronic HCV infection...
  14. pmc Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
    ..HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study)...
  15. doi request reprint Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Antivir Ther 17:411-23. 2012
    ....
  16. doi request reprint [The liver and Europe]
    J M Pawlotsky
    INSERM U955, Centre National de Reférence des Hépatites Virales B, C et delta, Laboratoire de Virologie, Universite Paris 12, Hopital Henri Mondor, 94010 Creteil Cedex, France
    Gastroenterol Clin Biol 33:903-7. 2009
    ..The future of hepatology as a specialty will depend on the success of this initiative...
  17. doi request reprint [Virologic techniques for the diagnosis and monitoring of hepatitis B]
    J M Pawlotsky
    Centre National de Référence des Hépatites B, C et delta, Laboratoire de Virologie, INSERM U841, Hopital Henri Mondor, Universite Paris 12, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Gastroenterol Clin Biol 32:S56-63. 2008
    ....
  18. pmc Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach
    Jean Michel Pawlotsky
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Gastroenterology 134:405-15. 2008
    ..This article discusses HBV virologic markers and tests, and their optimal use both for planning and reporting clinical trials and in clinical practice...
  19. ncbi request reprint Therapy of hepatitis C: from empiricism to eradication
    Jean Michel Pawlotsky
    Hopital Henri Mondor, Creteil, France
    Hepatology 43:S207-20. 2006
    ..New treatments and vaccines might make it possible to eradicate HCV in the future...
  20. ncbi request reprint The hepatitis C virus life cycle as a target for new antiviral therapies
    Jean Michel Pawlotsky
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Gastroenterology 132:1979-98. 2007
    ....
  21. pmc Therapeutic Implications of Hepatitis C virus Resistance to Antiviral Drugs
    Jean Michel Pawlotsky
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France and INSERM U955, Creteil, France
    Therap Adv Gastroenterol 2:205-19. 2009
    ..These new drugs all potentially select resistant viral variants both in vitro and in vivo, and resistance is therefore likely to become an important issue in clinical practice...
  22. ncbi request reprint Current and future concepts in hepatitis C therapy
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Creteil, France
    Semin Liver Dis 25:72-83. 2005
    ..Drug combinations will be tailored to the individual patient, based on baseline parameters and viral kinetics during therapy...
  23. ncbi request reprint Hepatitis C virus population dynamics during infection
    J M Pawlotsky
    Service de Virologie, Hopital Henri Mondor, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Curr Top Microbiol Immunol 299:261-84. 2006
    ..HCV quasispecies variability also has therapeutic implications, as the continuous generation and selection of fitter or truly resistant variants can allow the virus to escape control by antiviral drugs...
  24. pmc Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Virol 72:2795-805. 1998
    ....
  25. ncbi request reprint GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Med Virol 54:26-37. 1998
    ..GBV-C is sensitive to 3 mega units of interferon alfa administered three times per week in two-thirds of the patients, but relapse is constant with this dosage after treatment withdrawal...
  26. ncbi request reprint Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Virol Methods 85:11-21. 2000
    ..Given their respective performance, these three assays should be used in complementary fashion in the management of HBV-infected patients...
  27. doi request reprint Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    ..Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...
  28. pmc Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies
    L Castera
    Department of Virology EA 3489, Centre Hospitalier Universitaire Henri Mondor, Universite Paris XII, Creteil, France
    Gut 52:288-92. 2003
    ..The aim of the present study was to evaluate in patients with CHC and paired liver biopsies the relationship between the evolution of steatosis and that of fibrosis between the two biopsies...
  29. ncbi request reprint Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Virol Methods 79:227-35. 1999
    ..0 is not influenced by the HCV genotype. The relationship between values obtained with assays 1.0 and 2.0 on clinical specimens is not linear, indicating that HCV RNA titers cannot reliably be calculated from the results of version 1.0...
  30. doi request reprint Liver stiffness diminishes with antiviral response in chronic hepatitis C
    C Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France INSERM U955, Creteil, France
    Aliment Pharmacol Ther 34:656-63. 2011
    ..Transient elastography measures liver stiffness, which correlates with the hepatic fibrosis stage and has excellent accuracy for the diagnosis of cirrhosis in patients with chronic hepatitis C...
  31. ncbi request reprint What technique should be used for routine detection and quantification of HBV DNA in clinical samples?
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Virol Methods 65:245-53. 1997
    ..This study emphasizes the need for more sensitive, university standardised quantitative HBV DNA assays and for the definition of clinically relevant cutoffs with these assays...
  32. pmc Impact of smoking on histological liver lesions in chronic hepatitis C
    C Hezode
    Department of Hepatology Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    Gut 52:126-9. 2003
    ..Total lifetime tobacco consumption was recorded as the number of cigarette packs smoked per year (packs-years). Liver biopsy specimens were graded for histological activity and fibrosis according to the METAVIR scoring system...
  33. ncbi request reprint Standardization of hepatitis C virus RNA quantification
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Hepatology 32:654-9. 2000
    ....
  34. pmc Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, 94010 Creteil, France
    J Virol 73:6490-9. 1999
    ..These changes are associated with profound alterations of the natural outcome of HCV-related liver disease, raising the hypothesis of a causal relationship...
  35. ncbi request reprint Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections
    C Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris XII, 94010 Creteil Cedex, France
    J Viral Hepat 11:455-8. 2004
    ..These findings suggest that steatosis is a cytopathic lesion induced by HCV genotype 3, whereas HCV genotype 1 is not steatogenic per se or at the usual in vivo expression levels...
  36. ncbi request reprint Low HCV replication levels in end-stage hepatitis C virus-related liver disease
    C Duvoux
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Hepatol 31:593-7. 1999
    ..To clarify this point, we studied serum HCV RNA levels in patients with HCV liver disease at various stages, using a second-generation branched DNA (bDNA) assay...
  37. ncbi request reprint Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study
    C Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    Aliment Pharmacol Ther 17:1031-7. 2003
    ..To evaluate the effects of minimal to moderate alcohol consumption on the severity of histological lesions in patients with chronic hepatitis C...
  38. ncbi request reprint Treating hepatitis C in "difficult-to-treat" patients
    Jean Michel Pawlotsky
    Department of Virology, INSERM Unité 635, Henri Mondor Hospital, University of Paris XII, Creteil, France
    N Engl J Med 351:422-3. 2004
  39. pmc Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis
    L Castera
    Department of Virology EA 3489, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    Gut 53:420-4. 2004
    ..To investigate this hypothesis, we studied the relationship between steatosis evolution and HCV clearance after antiviral treatment in patients with chronic hepatitis C and paired liver biopsies...
  40. doi request reprint Occupational transmission of hepatitis C virus resulting from use of the same supermarket meat slicer
    L Bocket
    Laboratoire de Virologie, Centre Hospitalier Universitaire de Lille, France
    Clin Microbiol Infect 17:238-41. 2011
    ..A phylogenetic analysis showed a high percentage of nucleotide homology between the two patients' strains...
  41. pmc Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay
    Karine Gourlain
    Department of Virology, INSERM U635, Creteil, France
    J Clin Microbiol 43:1669-73. 2005
    ..These results emphasize the need for commercial HCV RNA quantification assays with a broader range of linear quantification, such as real-time PCR-based assays...
  42. pmc Analysis of ribavirin mutagenicity in human hepatitis C virus infection
    Stephane Chevaliez
    Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    J Virol 81:7732-41. 2007
    ..This study strongly undermines the hypothesis whereby ribavirin acts as an HCV mutagen in vivo...
  43. pmc Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay
    J M Pawlotsky
    Department of Bacteriology and Virology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Clin Microbiol 35:1734-9. 1997
    ..Subtyping of 1a and 1b is still not possible with the existing peptides, but discriminating between subtypes may not be necessary for routine use...
  44. ncbi request reprint Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Creteil, France
    Hepatology 46:22-31. 2007
    ....
  45. ncbi request reprint Hepatitis C virus: virology, diagnosis and management of antiviral therapy
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U 841, Hopital Henri Mondor, 94010 Creteil, France
    World J Gastroenterol 13:2461-6. 2007
    ..e. the endpoint of therapy...
  46. ncbi request reprint Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics
    Jean Michel Pawlotsky
    Department of Virology, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Semin Liver Dis 23:3-11. 2003
    ..These approaches will be particularly useful in studying the mechanisms of HCV treatment failure with new HCV inhibitors currently under development...
  47. ncbi request reprint Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication
    Magali Bouvier-Alias
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Hepatology 36:211-8. 2002
    ..Nevertheless, the total HCV core Ag assay cannot be used as a marker of viral replication for HCV RNA values below 20,000 IU/mL, limiting its use in the monitoring of late events during and after antiviral treatment...
  48. ncbi request reprint Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy
    F J Authier
    Groupe Nerf Muscle, Departement de Pathologie, Hopital Henri Mondor, Creteil, France
    Neurology 60:808-12. 2003
    ..MC may contain viral RNA, and tissues showing vasculitis may contain intracellular HCV. Local HCV replication remains to be evidenced...
  49. ncbi request reprint Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
    C Payan
    Laboratoire de Virologie, CHU Angers, France
    J Viral Hepat 12:405-13. 2005
    ..The modification of the HCV genotype pattern in France in the next 10 years may require new therapeutic strategies, and further survey studies...
  50. ncbi request reprint Diagnostic tests for hepatitis C
    J M Pawlotsky
    Department of Bacteriology and Virology and INSERM U99, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Hepatol 31:71-9. 1999
    ....
  51. ncbi request reprint Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis
    Christophe Duvoux
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, Universite Paris XII, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Transpl Int 15:3-9. 2002
    ..Cryoglobulinemia did not seem to be associated with more severe graft damage. Cryoglobulinemia-associated morbidity must be taken into account in the management of post-transplant HCV infection...
  52. ncbi request reprint Pathophysiology of hepatitis C virus infection and related liver disease
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Trends Microbiol 12:96-102. 2004
    ..The role of HCV proteins in hepatocarcinogenesis is unknown. Further progress in our understanding of HCV infection and pathogenesis awaits the advent of new model systems and technologies...
  53. ncbi request reprint Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    J Hepatol 39:S31-5. 2003
  54. ncbi request reprint [HCV non-responder patients: definition of non-response and treatment strategy]
    Patrick Marcellin
    Service d Hepatologie, INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 31:4S13-9. 2007
    ..The drugs, currently in phase 1 and 2, which will demonstrate their efficacy and safety, should not be available before several years...
  55. ncbi request reprint Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS
    Dominique Challine
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    J Med Virol 67:510-5. 2002
    ..These results argue against an in vivo interaction between HCV and EBV in patients with AIDS, and against a role of HCV infection in the occurrence of B-cell non-Hodgkin's lymphoma in these patients...
  56. ncbi request reprint Hepatitis C virus genetic variability: pathogenic and clinical implications
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, Creteil 94010, France
    Clin Liver Dis 7:45-66. 2003
    ..Further studies are needed to understand better the implications of HCV quasispecies diversity in the pathophysiology of HCV infection...
  57. ncbi request reprint Interferon-based therapy of hepatitis C
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Adv Drug Deliv Rev 59:1222-41. 2007
    ..Finally, insights into new hepatitis C drug developments are given...
  58. pmc Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification
    Stephane Chevaliez
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12
    J Clin Microbiol 46:1716-23. 2008
    ..Samples with HBV DNA concentrations above the upper limit of quantification need to be diluted and then retested. Broad use of fully automated real-time PCR assays should improve the management of patients with chronic HBV infection...
  59. ncbi request reprint Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy
    Muriel Soler
    Department of Virology EA 3489, Universite Paris XII, Creteil, France
    Virology 298:160-73. 2002
    ..In contrast, the overall quasispecies distribution of HCV genomes (including IRES sequences) might participate in regulation of hepatic and extrahepatic HCV replication...
  60. ncbi request reprint Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    J Hepatol 46:791-6. 2007
    ..Some patients receiving adefovir at the approved dose of 10 mg daily for chronic hepatitis B have a "suboptimal" virological response characterized by a slow and moderate decrease in viral replication...
  61. ncbi request reprint The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region
    Rozenn Brillet
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology and Institut National de la Sante et de la Recherche Medicale Unite 635, France
    J Infect Dis 195:432-41. 2007
    ..The nonstructural (NS) 5A protein of hepatitis C virus (HCV) has been suggested to contain an interferon (IFN) sensitivity-determining region (ISDR)...
  62. doi request reprint Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors
    Dominique Challine
    Department of Virology, French National Reference Center for Viral Hepatitis B, C and delta, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Gastroenterology 135:1185-91. 2008
    ..This study assessed the risk of HBV associated with different HBV serologic profiles in organ, tissue, and cell transplants, as well as the risk of HBV transmission from seronegative donors...
  63. ncbi request reprint Future therapies for hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris, Creteil, France
    Antivir Ther 11:397-408. 2006
    ....
  64. ncbi request reprint Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resist
    Muriel Soler
    Departament of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Antivir Ther 9:953-68. 2004
    ..Furthermore, no obvious nucleotide changes in the surrounding IRES region that might possibly affect oligonucleotide binding were detected...
  65. ncbi request reprint Use of virologic assays in the diagnosis and management of hepatitis C virus infection
    Stephane Chevaliez
    Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Clin Liver Dis 9:371-82, v. 2005
    ..The continuing development of test systems accompanied by new antiviral drugs and novel therapeutic approaches should lead to an optimization of the treatment of HCV infection...
  66. ncbi request reprint [The G virus: the orphan virus]
    J M Pawlotsky
    Service de Bacteriologie Virologie, Hopital Henri Mondor, Universite Paris XII, Creteil
    Presse Med 28:1882-3. 1999
    ..To date, this virus has not been associated with acute or chronic hepatitis and as such hepatitis G virus is a misnomer. This orphelin virus is thus still looking for the right name and perhaps an induced pathology...
  67. pmc Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load
    L Perrin
    Clinical Virology, University of Geneve, Switzerland, and Department of Bacteriology and Virology, Hopital Henri Mondor, Creteil, France
    J Clin Microbiol 44:4371-5. 2006
    ..These data indicate that the HPS-CTMHIV assay may be one of the tests of choice for monitoring viral load throughout the course of HIV infection and during highly active antiretroviral therapy...
  68. doi request reprint Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events
    M R Higgs
    Institut National de la Sante et de la Recherche Medicale INSERM, U955, Institut Mondor de Recherche Biomedicale, Creteil, France
    Oncogene 32:4683-93. 2013
    ..Together, these data provide a novel insight into the mechanisms involved in HCV-associated HCCs, strongly suggesting that c-Myc has a crucial contributory role in this process. ..
  69. ncbi request reprint Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C
    S Chevaliez
    Department of Virology, Henri Mondor Hospital, University of Paris XII, Paris, France
    J Viral Hepat 14:77-81. 2007
    ..Recent reports suggest that the virological response at week 4 could be used to tailor treatment duration, whatever the HCV genotype...
  70. doi request reprint Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis
    Aurélie Piodi
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, France
    Hepatology 48:16-27. 2008
    ..Importantly, we found no genetic or functional differences between genotype 3a core proteins from patients with and without HCV-induced steatosis...
  71. ncbi request reprint Use and interpretation of hepatitis C virus diagnostic assays
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, Creteil 94010, France
    Clin Liver Dis 7:127-37. 2003
    ..These improvements, and the development of new antiviral drugs (see the article by Drs. DeFrancesco and Rice elsewhere in this issue), should help to optimize the treatment of HCV infection...
  72. ncbi request reprint Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Hepatology 39:554-67. 2004
  73. ncbi request reprint Use and interpretation of virological tests for hepatitis C
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Hepatology 36:S65-73. 2002
    ..This article reviews the kinetics of HCV markers during acute and chronic HCV infection, together with current assays and their practical use in the management of HCV-infected patients...
  74. ncbi request reprint The nature of interferon-alpha resistance in hepatitis C virus infection
    Jean Michel Pawlotsky
    Department of Virology, Henri Mondor Hospital, Paris XII University, Creteil, France
    Curr Opin Infect Dis 16:587-92. 2003
    ..IFN resistance could also play a role in the virological response to IFN therapy through similar or different mechanisms. The involved mechanisms however remain unclear...
  75. ncbi request reprint Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users
    Yoann Morice
    Department of Virology and INSERM U635, French National Reference Center for Viral Hepatitis B, C and delta, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    J Med Virol 78:1296-303. 2006
    ..Regional transmission occurred in the recent past, leading to an embryonic genetic diversification of HCV-3a among local injecting drug user population...
  76. ncbi request reprint [Screening and diagnosis of hepatitis B and C]
    Stephane Chevaliez
    Laboratoire de Virologie, INSERM U635, Hopital Henri Mondor, Universite Paris 12, 94010 Creteil Cedex
    Rev Prat 55:615-23. 2005
    ..HCV genotype determination is used to tailor the treatment schedule to the individual patient. Treatment efficacy is assessed by means of molecular techniques to prove progressive and definitive viral clearance...
  77. pmc Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions
    Muriel Pellerin
    Department of Virology INSERM U635, Hopital Henri Mondor, Universite Paris XII, 94010 Creteil, France
    J Virol 78:4617-27. 2004
    ..This feature of quasispecies-distributed viruses could play an important role in various aspects of the viral life cycle and related disease...
  78. ncbi request reprint Serological viral testing of cadaveric cornea donors
    Dominique Challine
    Viral Emergency and Organ, Tissue, and Cell Donor Screening Laboratory, Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Transplantation 82:788-93. 2006
    ..Cadaveric donor serum is often of poor quality and frequently yields falsely positive results in serological assays that may result in the graft being needlessly discarded...
  79. ncbi request reprint Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    Hepatology 42:63-71. 2005
    ..In conclusion, daily cannabis smoking is significantly associated with fibrosis progression during CHC. Patients with ongoing CHC should be advised to refrain from regular cannabis use...
  80. ncbi request reprint HIV and hepatitis C virus RNA in seronegative organ and tissue donors
    Dominique Challine
    Viral Emergency and Organ, Tissue, and Cell Donor Screening Laboratory, Department of Virology INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Lancet 364:1611-2. 2004
    ..No HIV-seronegative, HIV RNA-positive donor was identified. Our data suggest that routine nucleic acid testing of organ and tissue donors might increase viral safety in transplantation...
  81. ncbi request reprint The concept of hepatitis B virus mutant escape
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Unioersité Paris 12, Creteil, France jean michel pawlotskyhmn aphp fr
    J Clin Virol 34:S125-9. 2005
    ....
  82. doi request reprint Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus
    Jean Michel Pawlotsky
    Department of Virology, Hopital Henri Mondor, Université Paris Est Créteil, France
    Hepatology 53:1742-51. 2011
    ....
  83. ncbi request reprint [Steasis and hepatitis C]
    Christophe Hezode
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil
    Gastroenterol Clin Biol 27:1091-5. 2003
  84. ncbi request reprint Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C
    Owonayo Oniankitan
    Department of Rheumatology, Henri Mondor Teaching Hospital, AP HP, Creteil, France
    J Rheumatol 31:107-9. 2004
    ..To describe the safety of tumor necrosis factor-a blockade in 2 patients with inflammatory rheumatic disease with chronic hepatitis B and C...
  85. ncbi request reprint Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    J Hepatol 41:935-42. 2004
    ....
  86. pmc Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study
    Syria Laperche
    Centre National de Référence pour les Hépatites B et C en Transfusion, Département des Agents Transmissible par le Sang, Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015 Paris, France
    J Clin Microbiol 43:733-9. 2005
    ....
  87. ncbi request reprint International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
    ..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response...
  88. ncbi request reprint The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice
    John G McHutchison
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Centre, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27707, USA
    J Hepatol 44:411-21. 2006
  89. pmc Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection
    Dimitri Lavillette
    LVRTG, ENS de Lyon, 46 allee d Italie, 69364 Lyon Cedex 07, France
    J Virol 79:6023-34. 2005
    ..These results provide new insights into the mechanisms of viral persistence and immune control of viremia...
  90. ncbi request reprint Immunological and virological effects of ribavirin in hepatitis C after liver transplantation
    Rafael Quadri
    Division of Gastroenterology and Hepatology, University Hospital, 1211 Geneva, Switzerland
    Transplantation 73:373-8. 2002
    ..A better understanding of the mechanisms of action of drugs currently used to manage hepatitis C would be helpful...
  91. ncbi request reprint Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
    Peter Simmonds
    Centre for Infectious Diseases, University of Edinburgh, Summerhall, Edinburgh, United Kingdom
    Hepatology 42:962-73. 2005
    ..In conclusion, these proposals provide the framework by which the HCV databases store and provide access to data on HCV, which will internationally coordinate the assignment of new genotypes and subtypes in the future...
  92. pmc Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro
    Valerie Castet
    INSERM U128, Montpellier, France
    J Virol 76:8189-99. 2002
    ..These results show that IFN-alpha acts primarily through its nonspecific antiviral effects and suggest that primary cultures of human hepatocytes may provide a good model to study intrinsic HCV resistance to IFN-alpha...
  93. ncbi request reprint A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 43:73-80. 2008
    ....
  94. ncbi request reprint Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
    Jean Pierre Bronowicki
    Department of Hepatology and Gastroenterology, INSERM U724, CHU de Nancy, Vandoeuvre les Nancy, France
    Gastroenterology 131:1040-8. 2006
    ..We aimed to investigate the role of ribavirin in HCV clearance during therapy and to evaluate the consequences of ribavirin discontinuation in patients infected with genotype 1 hepatitis C who cleared HCV RNA at week 24...
  95. pmc Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum
    Jean Jacques Lefrere
    centre hospitalo universitaire d Amiens, France
    J Clin Microbiol 42:2027-30. 2004
    ....
  96. ncbi request reprint Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6
    Esther Lukasiewicz
    Hepatology 45:258-9. 2007
  97. pmc Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C
    Laurent Castera
    Department of Hepatology and Gastroenterology, C H U Bordeaux, Hopital Haut Leveque, Pessac, France
    MedGenMed 7:39. 2005
  98. ncbi request reprint Treatment of hepatitis C: don't put all your eggs in one basket!
    Jean Michel Pawlotsky
    Gastroenterology 132:1611-5. 2007
  99. ncbi request reprint Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C
    Johan Westin
    Hepatology 45:1333-4; author reply 1334. 2007